News

BioSpace44m
AstraZeneca Makes $5.3B AI Bet With China’s CSPC for Chronic Disease Pills
Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.
Stocktwits on MSN54m
AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer
AstraZeneca (AZN) on Friday announced a strategic research collaboration with China-based CSPC Pharmaceuticals Group to ...